# US 2014/0155437 A1 · Prophylactic or therapeutic method for sjogren's syndrome

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0155437 A1
- Document ID: US20140155437A1
- Status: Published application
- Kind: A1
- Application number: 14/095,026
- Filed: 2013-12-03
- Published: 2014-06-05
- Earliest claimed: 2012-12-04
- Assignees: Takeda Pharmaceutical Company Limited
- Applicants: Takeda Pharmaceutical Company Limited
- Inventors: Nobutaka Suzuki; Takahiro Miyazaki; Takashi Ochi
- Web page: https://patentgrep.com/patent/US20140155437A1

## CPC

- C07D 213/89: with hetero atoms directly attached to the ring nitrogen atom
- A61K 31/44: Non condensed pyridines; Hydrogenated derivatives thereof
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/00: Drugs for immunological or allergic disorders
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides a prophylactic or therapeutic agent and a prophylactic or therapeutic method superior in the prophylaxis or treatment of Sjogren's syndrome. Provided are a prophylactic or therapeutic agent for Sjogren's syndrome, containing a compound represented by the formula (I): wherein each symbol is as defined in the Specification, or a pharmaceutically acceptable salt thereof, and a method for the prophylaxis or treatment of Sjogren's syndrome, including administering an effective amount of the compound represented by the formula (I) or a pharmaceutically acceptable salt thereof, to a subject in need thereof.

## Claims

### Claim 1

A method for the prophylaxis or treatment of Sjogren's syndrome, comprising administering an effective amount of a compound represented by the formula (I):
wherein n is an integer of 1-3;
R is each independently an aliphatic group, haloalkyl, aryl, arylalkyl, alkoxy, cycloalkoxy, haloalkoxy, aryloxy, arylalkoxy, alkylthio, a halogen atom, nitro, cyano, hydroxy, NR1CO2R2, C(O)N(R1)2, C(O)R2, CO2R2, OC(O)N(R1)2, OC(O)R2, N(R1)2 or NR1C(O)R2; or two adjacent R groups form, together with an atom bonded thereto, a condensed, saturated, unsaturated, or partially unsaturated 5- to 7-membered ring having 0, 1 or 2 hetero atoms selected from N, O and S;
R1 is each independently a hydrogen atom or an aliphatic group; and
R2 is an aliphatic group,
or a pharmaceutically acceptable salt thereof, to a subject in need thereof.

### Claim 2 (depends on 1)

The method according to claim 1, wherein R is an aliphatic group, alkoxy or haloalkoxy.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the compound represented by the formula (I) is N-{4-chloro-2-[(1-oxidopyridin-4-yl)carbonyl]phenyl}-4-(propan-2-yloxy)benzenesulfonamide.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the compound represented by the formula (I) is N-{4-chloro-2-[(1-oxidopyridin-4-yl)carbonyl]phenyl}-4-(tert-butyl)benzenesulfonamide.